ABSTRACT
No disponible
No disponible
Subject(s)
Humans , Male , Adult , Pilomatrixoma/diagnosis , Scalp Dermatoses/diagnosis , Diagnosis, DifferentialSubject(s)
Hair Diseases/surgery , Pilomatrixoma/surgery , Skin Neoplasms/surgery , Surgical Flaps , Adult , Humans , Male , Plastic Surgery Procedures/methodsABSTRACT
La morfea panesclerótica de la infancia es una rara variante de esclerodermia localizada, que aparece típicamente en la edad pediátrica, y que se caracterizapor la rápida progresión de una fibrosis cutánea profunda que alcanza fascia y músculo, determinando la aparición de contracturas articularesen flexión y ulceración cutánea.Aunque las manifestaciones de la esclerodermia sistémica están generalmente ausentes, este proceso afecta de forma importante la calidad de vida,por lo que el pronóstico es malo. En algunos casos los agentes inmunosupresores pueden retrasar el curso de la enfermedad. Recientemente se hancomunicado casos de mejoría de este cuadro mediante la utilización de la fototerapia. Aportamos un nuevo caso de esta entidad (AU)
Panesclerotic morphea of the childhood is a rare variant of localiced scleroderma that appears typically in the pediatric age, it is characterized by thefast progression of deep cutaneous fibrosis that reaches fascia and muscle, determining the appearance of articular contractures in flexion and cutaneousulceration. Although the features of systemic scleroderma are generally absent, this process affects severely the quality of life, the reason whythe prognosis is bad. In some cases the inmunosupressive agents can delay the course of the disease. Recently cases of improvement of this disorderwith phototerapia have been communicated. We described a new case of this entity (AU)
Subject(s)
Humans , Female , Child , Scleroderma, Localized/drug therapy , Scleroderma, Localized/diagnosis , Severity of Illness Index , Prostaglandins/therapeutic use , PUVA TherapyABSTRACT
Severe combined immunodeficiency (SCID) is a heterogeneous group of disorders characterized by a defect of T and B cell immunity with a genetic origin in most cases. Although the X-linked recessive form is most common (60-70%), there are autosomal recessive forms (20%) and spontaneous mutations. While SCID may present with many nosocomial infections, dermatophyte infections are not common. We reported a case of SCID which was associated with a widespread skin infection with Trichophyton mentagrophytes.
Subject(s)
Severe Combined Immunodeficiency/complications , Tinea Capitis/complications , Antifungal Agents/therapeutic use , Female , Griseofulvin/therapeutic use , Humans , Infant , Tinea Capitis/drug therapyABSTRACT
Alopecia areata is nonscarring telogenic alopecia of autoimmune etiology. It is estimated to be the presenting complaint in 2 % of dermatologic consultations, and can appear at any age although it is more common in young patients. Treatment depends on several factors, such as extent of the disease and age, and may be local or systemic. Local treatments aim to achieve hair regrowth, but do not alter the underlying condition, whereas systemic treatments can modify the course of the disease. In neither case does treatment provide a cure. In this article, we review most of the therapeutic options described in the literature for alopecia areata.
Subject(s)
Alopecia Areata/drug therapy , Adrenal Cortex Hormones/therapeutic use , Algorithms , Humans , ImmunotherapyABSTRACT
La alopecia areata es una alopecia no cicatricial telogénica de base autoinmune. Se estima que origina un 2 % de las consultas dermatológicas y puede aparecer a cualquier edad, aunque es más frecuente en pacientes jóvenes. Su tratamiento va a depender de varios factores, fundamentalmente de la extensión de la enfermedad, de la edad del paciente, así como de medidas locales y sistémicas. Mientras que los tratamientos locales tienen como objetivo conseguir el recrecimiento piloso, sin influir en la evolución de la enfermedad, los tratamientos sistémicos pueden interferir en la evolución de la misma, siendo ambos medidas paliativas. En este trabajo revisamos la mayoría de las opciones terapéuticas descritas en la literatura para la alopecia areata (AU)
Alopecia areata is nonscarring telogenic alopecia of autoimmune etiology. It is estimated to be the presenting complaint in 2 % of dermatologic consultations, and can appear at any age although it is more common in young patients. Treatment depends on several factors, such as extent of the disease and age, and may be local or systemic. Local treatments aim to achieve hair regrowth, but do not alter the underlying condition, whereas systemic treatments can modify the course of the disease. In neither case does treatment provide a cure. In this article, we review most of the therapeutic options described in the literature for alopecia areata (AU)
Subject(s)
Humans , Male , Female , Alopecia Areata/diagnosis , Alopecia Areata/therapy , Adrenal Cortex Hormones/therapeutic use , Cyclosporine/therapeutic use , Triamcinolone Acetonide/therapeutic use , Immunotherapy/methods , Phototherapy/methods , Photochemotherapy , Sulfasalazine/therapeutic use , Anthralin/therapeutic use , Minoxidil/therapeutic use , Administration, Topical , PUVA Therapy , Prostaglandins/therapeutic use , Tacrolimus/therapeutic use , Betamethasone Valerate/therapeutic use , Irritants/therapeutic use , Methylprednisolone/therapeutic use , Immunologic Factors/therapeutic useSubject(s)
Neurofibromatosis 1/complications , Sturge-Weber Syndrome/complications , Adult , Humans , MaleABSTRACT
No disponible
No disponible
Subject(s)
Female , Middle Aged , Humans , Acneiform Eruptions/complications , Acneiform Eruptions/diagnosis , Acneiform Eruptions/drug therapy , Metronidazole/therapeutic use , Immunohistochemistry/methods , Diagnosis, Differential , Keratinocytes , Keratinocytes/pathology , Keratinocytes/physiology , Protein Multimerization , Protein Multimerization/physiologySubject(s)
Acneiform Eruptions/chemically induced , Acneiform Eruptions/drug therapy , Antibodies, Monoclonal/adverse effects , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Metronidazole/therapeutic use , Acute Disease , Antibodies, Monoclonal, Humanized , Cetuximab , Female , Humans , Middle Aged , Remission InductionABSTRACT
La capecitabina es un agente antineoplásico utilizado para el tratamiento de pacientes con metástasis de tumores sólidos (mama y colon) en estadio avanzado. Se reconocen distintos efectos adversos, entre los cuales se encuentran los cutáneo-mucosos y, en concreto, la hiperpigmentación. Presentamos un caso de hiperpigmentación cutánea localizada secundaria a capecitabina en una mujer intervenida de cáncer de mama y en tratamiento durante un mes con este fármaco. El inicio del tratamiento se asoció con disestesias a nivel de manos y pies, así como aumento de la pigmentación de las mismas. La etiopatogénesis de tales manifestaciones es desconocida. Otros efectos adversos descritos, desde el punto de vista dermatológico, asociados a este fármaco asientan en uñas produciendo onicolisis, fragilidad, decoloración y distrofia
Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy
Subject(s)
Female , Middle Aged , Humans , Hyperpigmentation/chemically induced , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapyABSTRACT
Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesias and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy.
